Charles River Laboratories Long Term Debt 2010-2024 | CRL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories long term debt for 2023 was $2.647B, a 2.23% decline from 2022.
Charles River Laboratories long term debt for 2022 was $2.708B, a 1.65% increase from 2021.
Charles River Laboratories long term debt for 2021 was $2.664B, a 38.04% increase from 2020.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories long term debt for 2023 was $2.647B, a 2.23% decline from 2022.
Charles River Laboratories long term debt for 2022 was $2.708B, a 1.65% increase from 2021.
Charles River Laboratories long term debt for 2021 was $2.664B, a 38.04% increase from 2020.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$98B
Cencora (COR)	$48.9B
DiDi Global (DIDIY)	$23.6B
ICON (ICLR)	$17.7B
Natera (NTRA)	$16.6B
Viatris (VTRS)	$15.5B
Avantor (AVTR)	$15.4B
Revvity (RVTY)	$14.9B
BioMerieux (BMXMF)	$13.1B
CochLear (CHEOY)	$12.6B
Solventum (SOLV)	$12.5B
Medpace Holdings (MEDP)	$11.3B
Doximity (DOCS)	$10.8B
HealthEquity (HQY)	$8.6B
Sonic Healthcare (SKHHY)	$8.5B
Bausch + Lomb (BLCO)	$7B
Life Times (LTH)	$5.2B
Sotera Health (SHC)	$4.6B
Organon (OGN)	$4.1B
Surgery Partners (SGRY)	$3.9B
BrightSpring Health Services (BTSG)	$3.4B
PACS (PACS)	$3.3B
Alignment Healthcare (ALHC)	$2.6B
Concentras Parent (CON)	$2.5B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.3B
GeneDx Holdings (WGS)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.9B
Teladoc Health (TDOC)	$1.6B